Test Price
700 AEDโ Home Collection Available
X & Y Chromosome Chimerism Analysis (Sex-Mismatch Bone Marrow Transplant Monitoring) in UAE | 700 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by qualified medical professionals.
Hospital Extraction Only: Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The X & Y Chromosome Chimerism Analysis is a specialized post-transplant monitoring test that quantifies the ratio of donor-derived cells to recipient-derived cells in patients who have undergone sex-mismatched bone marrow transplantation. Using Fluorescence In-Situ Hybridization (FISH) with X and Y centromeric DNA probes, this assay detects engraftment status, early relapse, and graft rejection with exceptional precision.
| Parameter | Our Test (FISH Chimerism) | Closest Alternative (STR-PCR) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity โ Targeted X/Y centromeric enumeration | 95โ99% โ Amplification variability in mixed samples |
| Methodology | Fluorescence In-Situ Hybridization (FISH) โ Direct visualization | Short Tandem Repeat PCR with capillary electrophoresis |
| Turnaround Time (TAT) | 3โ4 Days โ Rapid clinical decision support | 5โ7 Days โ Extended analytical workflow |
| Cost (UAE) | 700 AED โ Inclusive of hospital collection logistics | 900โ1,200 AED โ Often excludes logistics |
| Sex-Mismatch Specificity | Optimized โ Gold standard for X/Y discordant transplants | Applicable but not sex-chromosome-specific |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh
Consultant Medical Genetics | DHA Registration ID: 9294403
"As a Consultant Medical Genetics specialist caring for post-transplant patients, I recognize the critical role precise chimerism monitoring plays in guiding clinical decisions. The X & Y Chromosome Chimerism Analysis delivers a highly accurate, quantitative measure of donor engraftment dynamics โ yet every result must be interpreted within the full context of the patient's clinical status, including blood counts, medication regimen, and physical exam findings. Our dedicated team ensures you receive compassionate, clear guidance throughout each step, so no one faces complex genetic data alone."
Important Medication Advisory
Do not discontinue, adjust, or modify any prescribed medication โ including immunosuppressants, corticosteroids, or prophylactic antibiotics โ without consulting your transplant physician. Altering your medication regimen based on test results alone can precipitate graft rejection, graft-versus-host disease (GVHD), or life-threatening infections.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed Without Physician Clearance):
- Active, untreated systemic infection or sepsis
- Severe thrombocytopenia (platelets <30,000/ยตL) โ increased bleeding risk with bone marrow aspiration
- Confirmed or suspected pregnancy (relative contraindication)
- Inability to provide informed consent
- Non-sex-mismatched transplant (this assay requires X/Y chromosomal disparity between donor and recipient)
Emergency Red Flags โ Seek Immediate Medical Attention If:
- Excessive or persistent bleeding at the collection site lasting >30 minutes
- Rapidly expanding hematoma, severe pain, or pressure at the aspiration site
- Fever >38.3ยฐC (101ยฐF) within 48 hours post-procedure
- Purulent discharge, erythema, or warmth suggesting localized infection
- Syncope, severe dizziness, or shortness of breath post-collection
Patient FAQ & Clinical Guidance
1. What exactly does the X & Y Chromosome Chimerism Analysis measure after my bone marrow transplant?
Snippet Answer: This test precisely measures the percentage of donor-derived cells versus recipient-derived cells in your blood or bone marrow using fluorescent DNA probes specific to the X and Y chromosomes, enabling early detection of graft failure or leukemic relapse.
The assay enumerates interphase nuclei bearing XX (female) and XY (male) signal patterns. In sex-mismatched transplants โ for example, a male recipient receiving female donor cells โ complete chimerism would show 100% XX (donor) cells. Mixed chimerism indicates coexistence of donor and residual recipient cells, while declining donor percentages may signal impending graft rejection. Your transplant team uses this quantitative data alongside other clinical markers to titrate immunosuppressive therapy and decide on interventions such as donor lymphocyte infusion (DLI).
2. How is the sample collected, and will the procedure cause significant pain?
Snippet Answer: Sample collection involves either a peripheral blood draw from your arm or a bone marrow aspiration from the hip bone under local anesthesia by an experienced hematologist, with only mild transient discomfort expected.
For peripheral blood collection, a standard venipuncture is performed โ similar to any routine blood test โ and takes less than five minutes with minimal discomfort. Bone marrow aspiration is conducted under strict aseptic conditions using local lidocaine anesthesia at the posterior iliac crest. Patients typically describe a brief pulling sensation rather than sharp pain. The entire procedure lasts approximately 15โ20 minutes. All collections are performed exclusively within accredited hospital facilities to ensure maximum safety and sterility.
3. What do my chimerism results mean, and when can I expect to receive them?
Snippet Answer: Your results report the precise donor chimerism percentage with a turnaround time of 3โ4 working days, indicating full donor engraftment, mixed chimerism, or loss of donor cells requiring clinical intervention.
Full donor chimerism (>95% donor cells) is the desired outcome, signifying successful engraftment. Mixed chimerism (5โ95% donor cells) may be stable and acceptable in certain reduced-intensity conditioning protocols, but declining donor percentages warrant urgent evaluation for graft rejection or disease relapse. Results below 5% donor cells indicate graft failure. Your report will include a detailed interpretive comment. We strongly recommend scheduling a telephonic post-test consultation with our clinical team at +971 54 548 8731 to discuss your results in context.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, stored, and processed within UAE sovereign boundaries. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under the regulatory oversight of the Dubai Health Authority (DHA).
Clinical & Logistical Metadata
| Test Name | X & Y Chromosome Chimerism Analysis (Sex-Mismatch Bone Marrow Transplant Monitoring) |
| Price (AED) | 700 |
| Turnaround Time | 3โ4 Days |
| Sample Type / Matrix | Bone Marrow Aspirate or Peripheral Blood (hospital collection only) |
| Methodology Used | Fluorescence In-Situ Hybridization (FISH) with X/Y centromeric DNA probes |
| ICD-10-CM Code | Z94.84 (Bone Marrow Transplant Status), Z48.22 (Encounter for Aftercare Following Bone Marrow Transplant), Z85.6 (Personal History of Leukemia) |
| LOINC Code | 96723-7 (Chimerism Analysis, Molecular Genetics) |
| DHA Facility License & Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians